{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:54:47Z","timestamp":1790895287358,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LIBBS, Brazil"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Accurate HER2 assessment is essential for breast cancer (BC) treatment, as it directs targeted therapy decisions and predicts patient prognosis. Even though immunohistochemistry (IHC) is widely used, manual scoring is susceptible to variability. This study was conducted to evaluate HER2 expression in HER2-negative breast cancer patients treated with neoadjuvant chemotherapy (NAC), using H-score and\n                      <jats:italic>ERBB2<\/jats:italic>\n                      mRNA quantification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study in breast cancer patients treated with NAC between 2017 and 2023. H-score was evaluated in 506 patients. For gene expression analyses, only tumors with available H-score and Ct\u2009\u2264\u200935 for all candidate reference genes were included, resulting in 173 evaluable cases for ERBB2 mRNA quantification. HER2-zero tumors were further stratified into HER2-null (H-score\u2009=\u20090) and HER2-ultralow (H-score 1\u2013120) groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among all 506 HER2-negative tumors, 54.6% were classified as HER2-low and 45.4% as HER2-zero. Within the HER2-zero subgroup, 47.4% showed measurable HER2 expression (HER2-ultralow). ERBB2 mRNA levels were significantly higher in HER2-low tumors compared to HER2-zero. Among HER2-zero, HER2-ultralow tumors had higher ERBB2 expression than HER2-null. Higher H-scores were associated with increased\n                      <jats:italic>ERBB2<\/jats:italic>\n                      transcript expression, according to Spearman correlation coefficient (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). HER2-null tumors were more frequently triple-negative.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Quantitative assessment by H-score and ERBB2 transcript analysis reveals heterogeneity within HER2-zero tumors, identifying a HER2-ultralow population with potentially distinct clinical behavior. These findings support the integration of continuous HER2 expression metrics into clinical decision-making and trial design, particularly in the era of HER2-targeted antibody\u2013drug conjugates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02334-4","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:35:58Z","timestamp":1783532158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["H-score and ERBB2 mRNA refine identification of HER2-low and HER2-ultralow breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Guilherme Parisotto","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Roberto","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Defante","family":"Telles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Facundo","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geisilene Russano","family":"de Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahira Lopes","family":"da Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Reinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovana","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazielle Morais","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Higor Kassouf","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Elisa Ribeiro","family":"da Silva Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia Silveira","family":"Graudenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"1","key":"2334_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.18632\/oncotarget.28680","volume":"16","author":"WL Hensing","year":"2025","unstructured":"Hensing WL, Podany EL, Sears JJ, Tapiavala S, Davis AA. Evolving concepts in HER2-low breast cancer: genomic insights, definitions, and treatment paradigms. Oncotarget. 2025;16(1):11\u201327.","journal-title":"Oncotarget"},{"issue":"1","key":"2334_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41571-024-00963-2","volume":"22","author":"J Drago","year":"2025","unstructured":"Drago J, Modi S. Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now? Nat Rev Clin Oncol. 2025;22(1):6\u20137.","journal-title":"Nat Rev Clin Oncol"},{"key":"2334_CR3","doi-asserted-by":"crossref","unstructured":"Monteiro MR, Nunes NC, Junior AA, Fede AB, Bretas GD, Souza CD, Mano M, da Silva JL. Antibody-drug conjugates in breast cancer: a comprehensive review of how to selectively deliver payloads. Breast Cancer: Targets Ther. 2024;16(0):51\u201370.","DOI":"10.2147\/BCTT.S448191"},{"issue":"22","key":"2334_CR4","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists guideline update. J Clin Oncol. 2023;41(22):3867\u201372.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2334_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini F, Chic N, Bras\u00f3-Maristany F, Par\u00e9 L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer. 2021;7(1):1.","journal-title":"npj Breast Cancer"},{"issue":"6","key":"2334_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41571-025-01016-y","volume":"22","author":"CJ Robbins","year":"2025","unstructured":"Robbins CJ, Bates KM, Rimm DL. HER2 testing: evolution and update for a companion diagnostic assay. Nat Rev Clin Oncol. 2025;22(6):408\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"2334_CR7","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322.","journal-title":"N Engl J Med"},{"issue":"8","key":"2334_CR8","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, Bescond LL, Filleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29(8):2110\u201320.","journal-title":"Nat Med"},{"issue":"4","key":"2334_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","volume":"8","author":"AI Fernandez","year":"2022","unstructured":"Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol. 2022;8(4):1\u20134.","journal-title":"JAMA Oncol"},{"key":"2334_CR10","first-page":"1","volume-title":"Basic Methods in Microscopy: Protocols and Concepts from Cells : a Laboratory Manual","author":"E. K. Goldman","year":"2006","unstructured":"Goldman EK. Light microscopy. In: DL S, RD G, editors. Basic methods in microscopy: protocols and concepts from cells: a laboratory manual. 2006. pp. 1\u201342."},{"issue":"7","key":"2334_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/0277-5379(91)90145-4","volume":"27","author":"RI Nicholson","year":"1991","unstructured":"Nicholson RI, Bouzubar N, Walker KJ, McClelland R, Dixon AR, Robertson JFR, et al. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer Clin Oncol. 1991;27(7):908\u201313.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"2334_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-3-030-20301-6_6","volume":"1152","author":"L Kalinowski","year":"2019","unstructured":"Kalinowski L, Saunus JM, Reed AEM, Lakhani SR. Advances in experimental medicine and biology. Adv Exp Med Biol. 2019;1152:75\u2013104.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"2334_CR13","first-page":"716","volume":"109","author":"KS McCarty","year":"1985","unstructured":"McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716\u201321.","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"2334_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jmoldx.2022.04.002","volume":"24","author":"K Xu","year":"2022","unstructured":"Xu K, Bayani J, Mallon E, Pond GR, Piper T, Hasenburg A, et al. Discordance between immunohistochemistry and Erb-B2 receptor tyrosine kinase 2 mRNA to determine human epidermal growth factor receptor 2 low status for breast cancer. J Mol Diagn. 2022;24(7):775\u201383.","journal-title":"J Mol Diagn"},{"issue":"1","key":"2334_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/jnci\/djz042","volume":"112","author":"A Prat","year":"2020","unstructured":"Prat A, Pascual T, Angelis CD, Gutierrez C, Llombart-Cussac A, Wang T, et al. HER2-Enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. JNCI. J Natl Cancer Inst. 2020;112(1):46\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"2334_CR16","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784\u201395.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2334_CR17","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38(12):1346\u201366.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2334_CR18","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett J, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364\u201382.","journal-title":"Arch Pathol Lab Med"},{"issue":"26","key":"2334_CR19","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1200\/JCO.22.01533","volume":"40","author":"B Moy","year":"2022","unstructured":"Moy B, Rumble RB, Carey LA. Chemotherapy and targeted therapy for HER2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor\u2013negative expert panel. Chemotherapy and targeted therapy for human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline rapid recommendation update. J Clin Oncol. 2022;40(26):3088\u201390.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2334_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"7","key":"2334_CR21","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41374-018-0057-0","volume":"98","author":"DK Meyerholz","year":"2018","unstructured":"Meyerholz DK, Beck AP. Principles and approaches for reproducible scoring of tissue stains in research. Lab Investig. 2018;98(7):844\u201355.","journal-title":"Lab Investig"},{"issue":"4","key":"2334_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2009\u2013 \u2206\u2206C T method. Methods. 2001;25(4):402\u20138.","journal-title":"Methods"},{"issue":"6","key":"2334_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101\u20138.","journal-title":"Nat Protoc"},{"key":"2334_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","volume":"72","author":"C Marchi\u00f2","year":"2021","unstructured":"Marchi\u00f2 C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123\u201335.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2334_CR25","doi-asserted-by":"publisher","first-page":"12129","DOI":"10.1038\/s41598-024-61957-9","volume":"14","author":"A Kapil","year":"2024","unstructured":"Kapil A, Spitzm\u00fcller A, Brieu N, Haneder S, Shumilov A, Meier A, et al. HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer. Sci Rep. 2024;14(1):12129.","journal-title":"Sci Rep"},{"issue":"3","key":"2334_CR26","doi-asserted-by":"publisher","first-page":"100309","DOI":"10.1016\/j.labinv.2023.100309","volume":"104","author":"H Tyburski","year":"2024","unstructured":"Tyburski H, Karakas C, Finkelman BS, Turner BM, Zhang H, Hicks DG. In ER-positive, HER2-negative breast cancers, HER2 mRNA levels correlate better with clinicopathologic features and oncotype DX recurrence score than HER2 immunohistochemistry. Lab Invest. 2024;104(3):100309.","journal-title":"Lab Invest"},{"key":"2334_CR27","doi-asserted-by":"crossref","unstructured":"Lee H, Ryu JM, Lee SK, Chae BJ, Yu J, Lee JE et al. HER2 mRNA score from quantitative ERBB2 mRNA expression of oncotype Dx. Am J Surg Pathol. 2025.","DOI":"10.1097\/PAS.0000000000002396"},{"issue":"16suppl","key":"2334_CR28","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1200\/JCO.2025.43.16_suppl.1116","volume":"43","author":"SA Nasser","year":"2025","unstructured":"Nasser SA, Zhang JA, Pathak T, Smith G, Shoffeitt LC, Madabhushi A, et al. HAI-score, an objective HER2 artificial intelligence method for accurate H-score estimation from IHC-stained breast cancer samples. J Clin Oncol. 2025;43(16suppl):1116\u20131116.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2334_CR29","doi-asserted-by":"publisher","first-page":"100398","DOI":"10.1016\/j.modpat.2023.100398","volume":"37","author":"Z Wen","year":"2024","unstructured":"Wen Z, Luo D, Wang S, Rong R, Evers BM, Jia L, et al. Deep learning\u2013based H-score quantification of immunohistochemistry-stained images. Mod Pathol. 2024;37(2):100398.","journal-title":"Mod Pathol"},{"issue":"22","key":"2334_CR30","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. DESTINY-Breast06 trial investigators. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391(22):2110\u201322.","journal-title":"N Engl J Med"},{"issue":"11","key":"2334_CR31","doi-asserted-by":"publisher","first-page":"100867","DOI":"10.1016\/j.modpat.2025.100867","volume":"38","author":"HU Schildhaus","year":"2025","unstructured":"Schildhaus HU, Badve S, D\u2019Arrigo C, Farshid G, Lebeau A, Peg V, Penault-Llorca F, et al. A global ring study: concordance between ventana PATHWAY Anti-HER2\/neu (4B5) companion diagnostic assay and comparators in detecting HER2-low breast cancer. Mod Pathol. 2025;38(11):100867.","journal-title":"Mod Pathol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02334-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02334-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:02:29Z","timestamp":1790892149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02334-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2334"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02334-4","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants. The study was approved by the Institutional Ethics Committee (number 57159722.3.2002.5404).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed the final manuscript and approved its submission for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have received support for the present manuscript (provision of study materials and article processing charges). S.R.: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: Novartis, MSD, Astra Zeneca, Daiichi, GSK, Pfizer, Roche\/Genentech, Lilly G.P.S.: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: Novartis, Astra Zeneca, Daiichi. L.R.S.: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: Novartis, Pfizer, Astra Zeneca, Daiichi. M.L.R.: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: Astra Zeneca. T.R.: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: Novartis, MSD, Astra Zeneca, Daiichi. H.K.V.: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: Novartis, MSD, GSK. V.V: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: Novartis, Pfizer, Lilly. A.E.C.: No conflict of interest to disclose.G.M.T.: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: Novartis, MSD. G.R.P.: No conflict of interest to disclose G.C.: No conflict of interest to disclose. J.M.: No conflict of interest. F.Z.: No conflict of interest. C.C: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: Novartis, MSD, Astra Zeneca. C.B.: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche\/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi, Daiichi. Stock or stock options: Thummi, MEDSIRM.S.G.: Payment or honoraria for lectures, presentations, speakers bureaus, or educational events: AstraZeneca.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"166"}}